Turn Therapeutics (TTRX) Operating Leases (2024 - 2026)

Turn Therapeutics' Operating Leases history runs 3 years deep, the most recent figure standing at $21539.0 for Q1 2026.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $21539.0 in Q1 2026; TTM through Mar 2026 was $21539.0, a N/A change from a year earlier, with the FY2025 full-year figure at $34081.0, down 57.6% from the prior year.
• Operating Leases declined to $21539.0 in Q1 2026 per TTRX's latest filing, from $34081.0 in the prior quarter.
• Across five years, Operating Leases topped out at $80376.0 in Q4 2024 and bottomed at $21539.0 in Q1 2026.
• The 3-year median for Operating Leases is $40212.5 (2025), against an average of $45585.0.
• Biggest YoY gain for Operating Leases was 57.6% in 2025; the steepest drop was 57.6% in 2025.
• Year by year, Operating Leases stood at $80376.0 in 2024, then sank by 57.6% to $34081.0 in 2025, then plunged by 36.8% to $21539.0 in 2026.
• Per Business Quant, the three latest TTRX Operating Leases figures stand at $21539.0 (Q1 2026), $34081.0 (Q4 2025), and $46344.0 (Q3 2025).